Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were acquired at an average cost of $3.86 per share, for a total transaction of $115,800.00. Following the purchase, the director now directly owns 30,000 shares in […]
Gain Therapeutics Inc (NASDAQ:GANX), a company specializing in the development of novel therapeutics to treat central nervous system and lysosomal storage diseases, has seen a notable insider transaction.
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
BETHESDA, Md., April 01, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies,.